Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more
Latest RNS from Hikma Pharmaceuticals PLC
- Hikma R&D Investor Spotlight Series
- director_pdmrDirector/PDMR Shareholding
- board_changeDirectorate change
- interim_resultsHalf-year Financial Report
Analyst consensus: Buy
As of 23 Sept 2026, 12 analysts rate Hikma Pharmaceuticals PLC a Buy, with 92% buy ratings and a mean price target of 2,036p (range 1,730p–2,657p), +28% vs the current price.
Valuation vs peers
Peer-relative fair value estimate: 3,381p against a current price of 1,611p (+110%), based on EV/EBITDA.